Stayble Therapeutics AB Logo

Stayble Therapeutics AB

Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.

STABL | ST

Overview

Corporate Details

ISIN(s):
SE0013513652 (+1 more)
LEI:
549300WD23DE1US21868
Country:
Sweden
Address:
Lennart Torstenssonsgatan 6, 412 56 Göteborg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Stayble Therapeutics AB is a clinical-stage pharmaceutical company focused on developing treatments for pain caused by lumbar disc herniation (LDH). The company's lead drug candidate, STA363, is a minimally invasive, injection-based therapy. It is designed as a second-line treatment for patients who do not find relief from conservative options like physiotherapy and analgesics. STA363 aims to bridge the therapeutic gap between conservative care and invasive surgery, offering a novel solution for individuals with sustained, disabling pain. The company's strategy involves advancing the candidate through clinical trials to become a market leader in this therapeutic area.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Stayble Therapeutics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Stayble Therapeutics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Stayble Therapeutics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea 291650
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden AROC
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden ACE
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan 4886
Astellas Pharma Inc. Logo
A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.
Japan 4503

Talk to a Data Expert

Have a question? We'll get back to you promptly.